O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+33.09%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$7.07B
AUM Growth
+$7.07B
(+20%)
Cap. Flow
-$90.9M
Cap. Flow
% of AUM
-1.29%
Top 10 Holdings %
Top 10 Hldgs %
31.27%
Holding
162
New
21
Increased
29
Reduced
28
Closed
28
Top Buys
| 1 |
BNR
Burning Rock Biotech
BNR
|
$128M |
| 2 |
Repare Therapeutics
RPTX
|
$106M |
| 3 |
Oric Pharmaceuticals
ORIC
|
$98.6M |
| 4 |
Biogen
BIIB
|
$63M |
| 5 |
Keros Therapeutics
KROS
|
$63M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$255M |
| 2 |
Gilead Sciences
GILD
|
$98.4M |
| 3 |
Pfizer
PFE
|
$98.3M |
| 4 |
HCA Healthcare
HCA
|
$63.8M |
| 5 |
Stryker
SYK
|
$61.8M |
Sector Composition
| 1 | Healthcare | 97.61% |
| 2 | Financials | 1.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
| $311M | 4.38% | 7,406,307 | – | – |
|
|
TCDA
2
DELISTED
Tricida, Inc. Common Stock
TCDA
| $264M | 3.72% | 9,614,280 | – | – |
|
|
ALXN
3
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $242M | 3.41% | 2,156,000 +84,615 | +4% | +$9.5M |
|
|
4
Ascendis Pharma
ASND
$11.8B
| $231M | 3.25% | 1,562,986 -1,724,414 | -52% | -$255M |
|
|
PRVL
5
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $206M | 2.9% | 13,822,463 | – | – |
|
6
Merck
MRK
$210B
| $200M | 2.82% | 2,589,100 | – | – |
|
7
Vertex Pharmaceuticals
VRTX
$100B
| $193M | 2.72% | 666,100 -71,300 | -10% | -$20.7M |
|
|
8
Biogen
BIIB
$19.4B
| $192M | 2.7% | 715,900 +235,500 | +49% | +$63M |
|
9
Passage Bio
PASG
$22.7M
| $190M | 2.68% | 6,962,899 | – | – |
|
10
Iovance Biotherapeutics
IOVA
$807M
| $182M | 2.57% | 6,645,100 +1,096,774 | +20% | +$30.1M |
|
|
TPTX
11
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $177M | 2.5% | 2,745,327 | – | – |
|
12
Boston Scientific
BSX
$156B
| $170M | 2.4% | 4,847,300 | – | – |
|
13
Bristol-Myers Squibb
BMY
$96B
| $169M | 2.39% | 2,882,200 +407,400 | +16% | +$24M |
|
14
Natera
NTRA
$23.1B
| $162M | 2.27% | 3,240,514 -106,486 | -3% | -$5.31M |
|
|
HZNP
15
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $159M | 2.24% | 2,867,910 +526,210 | +22% | +$29.2M |
|
|
MRTX
16
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $151M | 2.13% | 1,324,100 -99,200 | -7% | -$11.3M |
|
17
Alector
ALEC
$238M
| $146M | 2.06% | 5,975,322 -2,352,369 | -28% | -$57.5M |
|
18
Neurocrine Biosciences
NBIX
$13.8B
| $145M | 2.04% | 1,185,915 +30,900 | +3% | +$3.77M |
|
19
Arcutis Biotherapeutics
ARQT
$1.86B
| $141M | 1.99% | 4,673,850 | – | – |
|
|
BNR
20
Burning Rock Biotech
BNR
$93.6M
| $128M | 1.8% | +4,746,071 | New | +$128M |
|
21
Humana
HUM
$36.5B
| $109M | 1.53% | 280,300 | – | – |
|
|
22
Repare Therapeutics
RPTX
$71.7M
| $106M | 1.5% | +3,426,325 | New | +$106M |
|
|
23
Oric Pharmaceuticals
ORIC
$994M
| $98.6M | 1.39% | +2,921,967 | New | +$98.6M |
|
24
Agios Pharmaceuticals
AGIO
$2.19B
| $92.4M | 1.3% | 1,728,421 +75,725 | +5% | +$4.05M |
|
25
DexCom
DXCM
$29.5B
| $91.8M | 1.29% | 226,400 -111,600 | -33% | -$45.2M |
|